Acute cardiorespiratory breathlessness accounts for one in eight of all emergency hospitalizations. Early, noninvasive diagnostic testing is a clinical priority that allows rapid triage and treatment. Here, we sought to find and replicate diagnostic breath volatile organic compound (VOC) biomarkers of acute cardiorespiratory disease and understand breath metabolite network enrichment in acute disease, with a view to gaining mechanistic insight of breath biochemical derangements. We collected and analyzed exhaled breath samples from 277 participants presenting acute cardiorespiratory exacerbations and aged-matched healthy volunteers. Topological data analysis phenotypes differentiated acute disease from health and acute cardiorespiratory exacerbation subtypes (acute heart failure, acute asthma, acute chronic obstructive pulmonary disease, and community-acquired pneumonia). A multibiomarker score (101 breath biomarkers) demonstrated good diagnostic sensitivity and specificity (≥80%) in both discovery and replication sets and was associated with all-cause mortality at 2 years. In addition, VOC biomarker scores differentiated metabolic subgroups of cardiorespiratory exacerbation. Louvain clustering of VOCs coupled with metabolite enrichment and similarity assessment revealed highly specific enrichment patterns in all acute disease subgroups, for example, selective enrichment of correlated C5-7 hydrocarbons and C3-5 carbonyls in heart failure and selective depletion of correlated aldehydes in acute asthma. This study identified breath VOCs that differentiate acute cardiorespiratory exacerbations and associated subtypes and metabolic clusters of disease-associated VOCs.
Introduction Patients presenting with acute undifferentiated breathlessness are commonly encountered in admissions units across the UK. Existing blood biomarkers have clinical utility in distinguishing patients with single organ pathologies but have poor discriminatory power in multifactorial presentations. Evaluation of volatile organic compounds (VOCs) in exhaled breath offers the potential to develop biomarkers of disease states that underpin acute cardiorespiratory breathlessness, owing to their proximity to the cardiorespiratory system. To date, there has been no systematic evaluation of VOC in acute cardiorespiratory breathlessness. The proposed study will seek to use both offline and online VOC technologies to evaluate the predictive value of VOC in identifying common conditions that present with acute cardiorespiratory breathlessness. Methods and analysis A prospective real-world observational study carried out across three acute admissions units within Leicestershire. Participants with self-reported acute breathlessness, with a confirmed primary diagnosis of either acute heart failure, community-acquired pneumonia and acute exacerbation of asthma or chronic obstructive pulmonary disease will be recruited within 24 hours of admission. Additionally, school-age children admitted with severe asthma will be evaluated. All participants will undergo breath sampling on admission and on recovery following discharge. A range of online technologies including: proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry and offline technologies including gas chromatography mass spectroscopy and comprehensive two-dimensional gas chromatography-mass spectrometry will be used for VOC discovery and replication. For offline technologies, a standardised CE-marked breath sampling device (ReCIVA) will be used. All recruited participants will be characterised using existing blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I and blood eosinophil levels and further evaluated using a range of standardised questionnaires, lung function testing, sputum cell counts and other diagnostic tests pertinent to acute disease. Ethics and dissemination The National Research Ethics Service Committee East Midlands has approved the study protocol (REC number: 16/LO/1747). Integrated Research Approval System (IRAS) 198921. Findings will be presented at academic conferences and published in peer-reviewed scientific journals. Dissemination will be facilitated via a partnership with the East Midlands Academic Health Sciences Network and via interaction with all UK-funded Medical Research Council and Engineering and Physical Sciences Research Council molecular pathology nodes. Trial registration number NCT03672994.
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airways disease. The epithelial-derived ‘alarmin’ IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We sought to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: We undertook a single-centre, randomised, double-blinded, placebo-controlled, phase IIa trial in moderate-to-very severe COPD. Participants received astegolimab 490mg (n=42) or placebo (n=39), every 4 weeks over 44 weeks. Primary endpoint was exacerbation rate over 48 weeks with pre-specified subgroup analysis by baseline blood eosinophil count. Secondary endpoints included Saint George’s Respiratory Questionnaire for COPD (SGRQ-C), FEV1, blood and sputum cell counts, and safety and tolerability. Results: The 48-week exacerbation rate in the astegolimab group relative to placebo was 0.78 (0.53 -0 1.14; p=0.195) in the whole group and 0.69 (0.39 - 1.21) and 0.83 (0.49 - 1.40) in subjects below or above the median baseline blood eosinophil count (170 cells/µL). In the astegolimab group versus placebo the mean difference for SGRQ-C and FEV1 was –3.3 (-6.4 to -0.2; p=0.039) and 40ml (-10 to 90; p=0.094), respectively. The differences in geometric mean ratios for blood and sputum eosinophil counts were 0.59 (0.51 - 0.69; p<0.001) and 0.25 (0.19 - 0.33; p<0.001). Incidence of treatment-emergent adverse events was similar between groups. Conclusion: Astegolimab did not reduce 48-week COPD exacerbation rate significantly in the whole group, subgroup analyses suggested more benefit in subjects with lower blood eosinophil counts.